Vadadustat
- Generic Name
- Vadadustat
- Brand Names
- Vafseo
- Drug Type
- Small Molecule
- Chemical Formula
- C14H11ClN2O4
- CAS Number
- 1000025-07-9
- Unique Ingredient Identifier
- I60W9520VV
- Background
One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in erythropoietin (EPO) production. The treatment of anemia associated with chronic kidney disease (CKD) has traditionally involved the administration of exogenous erythropoiesis-st...
- Indication
Vadadustat is indicated for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
- Associated Conditions
- Symptomatic Anemia
- Associated Therapies
- -
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 3554
- Registration Number
- NCT02892149
- Locations
- πΊπΈ
AMPM Research Clinic, Miami, Florida, United States
π¬π§Research Site, Doncaster, South Yorkshire, United Kingdom
πΊπ¦Research Site #1, Cherkassy, Ukraine
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 369
- Registration Number
- NCT02865850
- Locations
- πΊπ¦
Research Site, Zhytomyr, Ukraine
πΊπΈResearch Site #1, Chattanooga, Tennessee, United States
π·πΊResearch Site #2, Kemerovo, Russian Federation
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2016-02-11
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 1725
- Registration Number
- NCT02680574
- Locations
- π·πΈ
Research Site #3, Belgrade, Serbia
πΏπ¦Research Site #1, Durban, KwaZulu-Natal, South Africa
πΏπ¦Research Site #2, Durban, KwaZulu-Natal, South Africa
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 1751
- Registration Number
- NCT02648347
- Locations
- π¬π§
Research Site, Swansea, United Kingdom
πΏπ¦Research Site #1, Durban, KwaZulu-Natal, South Africa
πΏπ¦Research Site #2, Durban, KwaZulu-Natal, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.